Syndeio novel target discovery program

The Syndeio novel target discovery program is a confidential, discovery-stage initiative by Syndeio Biosciences focused on identifying new therapeutic targets to address synaptic dysfunction. This program is part of the company's broader strategy to develop treatments for mental health, neuropsychiatric, and cognitive disorders. While the specific biological targets and drug modalities (such as small molecules or biologics) have not yet been disclosed, the research aims to restore synaptic health in conditions where synaptic communication is impaired. The program is currently in the early discovery phase.

Other names

Confidential discovery program